| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A simple way of doing the complex but utmost important things: cancer pain management
|
Singhal, S.
|
|
|
34 |
5 |
p. 496
|
artikel
|
| 2 |
Bureaucracy or streamlining the rules in ‘Good Clinical Practice (GCP)’—has equipoise occurred?
|
Kotakonda, H.K.
|
|
|
34 |
5 |
p. 497-498
|
artikel
|
| 3 |
Corrigendum to “1773P Prediction of chemotherapy response in muscle-invasive bladder cancer: A machine learning approach”
|
Shkolyar, E.
|
|
|
34 |
5 |
p. 502
|
artikel
|
| 4 |
Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer ☆
|
Chowdhury, S.
|
|
|
34 |
5 |
p. 477-485
|
artikel
|
| 5 |
Editorial Board
|
|
|
|
34 |
5 |
p. iii
|
artikel
|
| 6 |
Elacestrant: who are optimal candidates for the first oral SERD?
|
Lipsyc-Sharf, M.
|
|
|
34 |
5 |
p. 449-451
|
artikel
|
| 7 |
Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial
|
Remon, J.
|
|
|
34 |
5 |
p. 468-476
|
artikel
|
| 8 |
Reply to letter to the editor “Bureaucracy or Streamlining the Rules in “Good Clinical Practice (GCP)” - Has Equipoise Occurred?” by H. K. Kotikonda, V. G. Jonnalagadda and S. R. Venna
|
Perez-Gracia, J.L.
|
|
|
34 |
5 |
p. 498-499
|
artikel
|
| 9 |
Reply to the Letter to the Editor “A simple way of doing the complex but utmost important things: cancer pain management” by S. Singhal, M. Verma and D. Kukreja
|
Fallon, M.T.
|
|
|
34 |
5 |
p. 496-497
|
artikel
|
| 10 |
Table of Contents
|
|
|
|
34 |
5 |
p. i-ii
|
artikel
|
| 11 |
Unintrusive multi-cancer detection by circulating cell-free DNA methylation sequencing (THUNDER): development and independent validation studies ☆
|
Gao, Q.
|
|
|
34 |
5 |
p. 486-495
|
artikel
|
| 12 |
Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline ☆
|
Falanga, A.
|
|
|
34 |
5 |
p. 452-467
|
artikel
|
| 13 |
VP2-2023: Dostarlimab+chemotherapy for the treatment of primary advanced or recurrent (A/R) endometrial cancer (EC): A placebo (PBO)-controlled randomised phase III trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)
|
Mirza, M.R.
|
|
|
34 |
5 |
p. 500-501
|
artikel
|
Tijdschrift beschrijving